Skip to main content
SpringerLink
Log in
Book cover

Geriatric Medicine pp 337–354Cite as

Hematologic Malignancies

  • Chapter

  • 236 Accesses

Abstract

The hematologic malignancies are a diverse group of disorders that are frequently considered together because they consist of clonal expansions of hematopoietic cells. The cell of origin of many of the hematologic malignancies is known. The stage of differentiation of the transformed cell essentially determines the phenotype of the disorder. Before considering the types of hematologic malignancies, we will review the normal differentiation pathway of hematopoietic cells.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Preti A, Kantarjian HM. Management of adult acute lym- 20. phocytic leukemia: present issues and key challenges. J Clin Oncol. 1994; 12: 1312–1322.

    PubMed  CAS  Google Scholar 

  2. Hoelzer DF. Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. Hematol Oncol Clin North 21. Am. 1993; 7: 139–160.

    CAS  Google Scholar 

  3. Harousseau J-L. Is intensive treatment beneficial to elderly 22. patients with ANLL? Hematol Oncol. 1993; 11: 4–8.

    PubMed  Google Scholar 

  4. Foon KA, Zighelboim J, Yale C, et al. Intensive chemotherapy is the treatment of choice for elderly patients with 23. acute myelogenous leukemia. Blood. 1981; 58: 467–470.

    PubMed  CAS  Google Scholar 

  5. Tallman MS, Rowe JM. Acute promyelocytic leukemia: a paradigm for differentiation therapy with retinoic acid. Blood Rev. 1994; 8: 70–78. 24.

    Google Scholar 

  6. Kourdes PA, Bennett JM. Morphology and classification of myelodysplastic syndromes. Hematol Oncol Clin North 25. Am. 1992; 6: 485–500.

    Google Scholar 

  7. Mufti GJ. A guide to risk assessment in the primary 26. myelodysplastic syndrome. Hematol Oncol Clin North Am. 1992; 6: 587–606.

    PubMed  CAS  Google Scholar 

  8. Noel P, Solberg LA. Myelodysplastic syndromes. Crit Rev 27. Oncol Hematol. 1992; 12: 193–215.

    CAS  Google Scholar 

  9. Kantarjian HM, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia: a concise update. Blood. 1993; 28. 82: 691–703.

    Google Scholar 

  10. Tura S, Baccarani M, Zuffa E, et al. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 29. 1994; 330: 820–825.

    Google Scholar 

  11. Miller JS, McGlave PB. Therapy for chronic myelogenous leukemia with marrow transplantation. Curr Opin Oncol. 1993; 5: 262–269.

    Article  PubMed  CAS  Google Scholar 

  12. Prchal JT, Prchal JF. Evolving understanding of the cellular defect in polycythemia vera: applications for its clinical diagnosis and molecular pathophysiology. Blood. 1994; 83: 1–4.

    PubMed  CAS  Google Scholar 

  13. Tura S. The management of elderly patients with myeloproliferative disorders. Hematol Oncol. 1993; 11: 39–41.

    PubMed  Google Scholar 

  14. Silver RT. Interferon-a2b: a new treatment for polycythemia vera. Ann Intern Med. 1993; 119: 1091–1092.

    PubMed  CAS  Google Scholar 

  15. Benbassat J, Gilon D, Penchas S. The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. Am J Hematol. 1990; 33: 128–135.

    Article  PubMed  CAS  Google Scholar 

  16. Oscier DG. Cytogenetic and molecular abnormalities in chronic lymphocytic leukaemia. Blood Rev. 1994; 8: 88–97.

    Article  PubMed  CAS  Google Scholar 

  17. Rozman C, Montserrat E, Rodriquez-Fernandez JM, et al. Bone marrow histologic pattern, the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood. 1984; 64: 642.

    PubMed  CAS  Google Scholar 

  18. Keating MJ, McLaughlin P, Plunkett W, et al. Fludarabine-present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol. 1994; 5 (suppl 2): 79–83.

    Article  PubMed  Google Scholar 

  19. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized controlled clinical trial. N Engl J Med. 1988; 319: 902.

    Article  Google Scholar 

  20. Smalley RV, Connors J, Tuttle RL, et al. Splenectomy vs alpha interferon: a randomized study in patients with previously untreated hairy cell leukemia. Am J Hematol. 1992; 41: 13–18.

    Article  PubMed  CAS  Google Scholar 

  21. Saven A, Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med. 1994; 330: 691–697.

    Article  PubMed  CAS  Google Scholar 

  22. Crawford J, Eye MK, Cohen HJ. Evaluation of monoclonal gammopathies in the “well” elderly. Am J Med. 1987; 82: 39–45.

    Article  PubMed  CAS  Google Scholar 

  23. Kyle RA. Plasma cell proliferative disorders. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, et al., eds. Hematology Basic Principles and Practice. New York: Churchill-Livingstone; 1991: 1021–1038.

    Google Scholar 

  24. Kyle RA. Current concepts on monoclonal gammopathies. Aust NZ J Med. 1992; 22: 291–302.

    Article  CAS  Google Scholar 

  25. Gautier M, Cohen HJ. Multiple myeloma in the elderly. J Am Geriatr Soc. 1994; 42: 653–664.

    PubMed  CAS  Google Scholar 

  26. Paquette RL, Berenson J, Lichtenstein A, et al. Oncogenes in multiple myeloma: point mutation of N-ras. Oncogene. 1990; 5: 1659–1663.

    CAS  Google Scholar 

  27. Bataille R, Chappard D, Klein B. Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am. 1992; 6: 285–295.

    PubMed  CAS  Google Scholar 

  28. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992; 10: 334–342.

    PubMed  CAS  Google Scholar 

  29. Buzaid AC, Durie BGM. Management of refractory myeloma: a review. J Clin Oncol. 1988; 6: 889–905.

    PubMed  CAS  Google Scholar 

  30. Sonneveld P, Durie BGM, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet. 1992; 340: 255–259.

    Article  PubMed  CAS  Google Scholar 

  31. Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med. 1990; 322: 1430–1434.

    Article  PubMed  CAS  Google Scholar 

  32. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for apatient with plasma cell leukemia. Blood. 1991; 78: 1198 1204.

    Google Scholar 

  33. Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treat ment of anemia associated with multiple myeloma. N Engl J Med. 1990; 322: 1693–1699.

    CAS  Google Scholar 

  34. Crawford J, Cox EB, Cohen HJ. Evaluation of hyperviscosity in monoclonal gammopathies. Am J Med. 1985; 79: 13.

    Article  PubMed  CAS  Google Scholar 

  35. Gertz MA, Kyle RA, Greipp PR. Response rates and sur vival in primary systemic amyloidosis. Blood. 1991; 77: 257–262.

    PubMed  CAS  Google Scholar 

  36. Weisenburger DD. Epidemiology of non-Hodgkin’s lymphoma: recent findings regarding an emerging epidemic. Ann Oncol. 1994; 5 (suppl 1): 19–24.

    Article  PubMed  Google Scholar 

  37. Gaidano G, Dalla-Favera R. Biologic and molecular char acterization of non-Hodgkin’s lymphoma. Curr Opin Oncol. 1993; 5: 776–784.

    Article  PubMed  CAS  Google Scholar 

  38. Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting. V. Aggressive com bined modality treatment. Semin Hematol. 1988; 25: 11.

    PubMed  CAS  Google Scholar 

  39. Shipp MA. Prognostic factors in aggressive non-Hodgkin’s lymphoma: who has “high-risk” disease? Blood. 1994; 83: 1165–1173.

    PubMed  CAS  Google Scholar 

  40. Dixon DO, Neilan B, Jones SE, et al. Effect of age ontherapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol. 1986; 4: 295–305.

    PubMed  CAS  Google Scholar 

  41. Vose JM, Armitage JO, Weisenburger DD, et al. The im portance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 1988; 6: 1838–1844.

    PubMed  CAS  Google Scholar 

  42. Mauch PM, Kalish LA, Kadin M, et al. Patterns of presentation of Hodgkin disease: implications for etiology and pathogenesis. Cancer. 1993; 71: 2062–2071.

    Article  PubMed  CAS  Google Scholar 

  43. Kaufman D, Lungo DL. Hodgkin’s disease. Clin Rev Oncol/Hematol. 1992; 13: 135–187.

    Article  CAS  Google Scholar 

  44. Mauch PM. Controversies in the management of early stage Hodgkin’s disease. Blood. 1994; 83: 318–329.

    PubMed  CAS  Google Scholar 

  45. DeVita VT, Hubbard SM. Drug therapy: Hodgkin’s dis ease. N Engl J Med. 1993; 328: 560–565.

    Article  PubMed  Google Scholar 

  46. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992; 327: 1478–1484.

    Article  PubMed  CAS  Google Scholar 

  47. Prosnitz LR, Roberts KB. Combined chemotherapy and radiotherapy for Hodgkin’s disease. Oncology. 1992;6: 113–137.

    Google Scholar 

  48. Mir R, Anderson J, Strauchen J, et al. Hodgkin disease in patients 60 years of age or older. Cancer. 1993; 71: 1857–1866.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Marc Gautier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harvey Jay Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Henry L. Schwartz Department of Geriatrics and Adult Development, The Mount Sinai Medical Center, 10029-6574, New York, NY, USA

    Christine K. Cassel M.D. (Professor and Chairman) & Diane E. Meier M.D. (Associate Professor) (Professor and Chairman) &  (Associate Professor)

  2. Center for Study of Aging and Geriatric Research Education and Clinical Center, Duke University Medical Center, 27710, Durham, NC, USA

    Harvey J. Cohen M.D. (Director) (Director)

  3. University of Washington Medical Center, 98195, Seattle, WA, USA

    Eric B. Larson M.D., M.P.H. (Medical Director) (Medical Director)

  4. Gerontology Division, Harvard Medical School, Brigham and Women’s Hospital, 02115, Boston, MA, USA

    Neil M. Resnick M.D. (Chief) (Chief)

  5. Geriatric Research Education and Clinical Center, Sepulveda VA Medical Center, 91343, Sepulveda, CA, USA

    Laurence Z. Rubenstein M.D., M.P.H. (Director) (Director)

  6. Department of Medicine, University of Chicago, 60637, Chicago, IL, USA

    Leif B. Sorensen M.D. (Professor and Vice Chairman) (Professor and Vice Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gautier, M., Cohen, H.J. (1997). Hematologic Malignancies. In: Cassel, C.K., et al. Geriatric Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-2705-0_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-2705-0_25

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4757-2707-4

  • Online ISBN: 978-1-4757-2705-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation